{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:02:07Z","timestamp":1792443727176,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.cgh.2014.03.035","type":"journal-article","created":{"date-parts":[[2014,4,30]],"date-time":"2014-04-30T15:31:57Z","timestamp":1398871917000},"page":"1887-1893.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis"],"prefix":"10.1016","volume":"12","author":[{"given":"Mark T.","family":"Osterman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faten N.","family":"Aberra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Liakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Shafran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Nessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Brensinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Gilroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2014.03.035_bib1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.gastro.2007.05.051","article-title":"Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort","volume":"133","author":"Froslie","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.03.035_bib2","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1053\/j.gastro.2010.11.058","article-title":"The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease","volume":"140","author":"Lewis","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.03.035_bib3","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1002\/ibd.22861","article-title":"Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies","volume":"18","author":"Mao","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.03.035_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A\u00a0simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2014.03.035_bib5","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1053\/j.gastro.2006.12.037","article-title":"A\u00a0meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis","volume":"132","author":"Su","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.03.035_bib6","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/ibd.22863","article-title":"Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFalpha blocking agents","volume":"18","author":"Molander","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.03.035_bib7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.crohns.2011.11.002","article-title":"Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis","volume":"6","author":"De Vos","year":"2012","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2014.03.035_bib8","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1097\/MIB.0b013e31829b2a37","article-title":"Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy","volume":"19","author":"Vos","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.03.035_bib9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1155\/2007\/862917","article-title":"Delayed-release oral mesalamine 4.8 g\/day (800 mg tablets) compared to 2.4 g\/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial","volume":"21","author":"Hanauer","year":"2007","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.cgh.2014.03.035_bib10","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1111\/j.1572-0241.2005.00248.x","article-title":"Delayed-release oral mesalamine at 4.8 g\/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial","volume":"100","author":"Hanauer","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2014.03.035_bib11","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1053\/j.gastro.2009.08.069","article-title":"Delayed-release oral mesalamine 4.8 g\/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis","volume":"137","author":"Sandborn","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.03.035_bib12","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1365-2036.2010.04575.x","article-title":"Randomised clinical trial: delayed-release oral mesalazine 4.8 g\/day vs 2.4 g\/day in endoscopic mucosal healing\u2014ASCEND I and II combined analysis","volume":"33","author":"Lichtenstein","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2014.03.035_bib13","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1365-2036.2008.03688.x","article-title":"MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations","volume":"27","author":"Lichtenstein","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2014.03.035_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ibd.20580","article-title":"Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis","volume":"15","author":"Kamm","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2014.03.035_bib15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.gastro.2013.03.025","article-title":"The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis","volume":"145","author":"Feagan","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2014.03.035_bib16","first-page":"2031","article-title":"Are there any differences in the efficacy and safety of different formulations of oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? Evidence from Cochrane Reviews","volume":"19","author":"Feagan","year":"2013","journal-title":"Inflamm Bowel Dis"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356514006351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356514006351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:15:42Z","timestamp":1761542142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356514006351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S1542356514006351"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2014.03.035","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2014.03.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 AGA Institute. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}